Advanced Silicon Group

Advanced Silicon Group is taking nanowire biosensors from concept to reality. Using novel patented and proprietary silicon nanowire technology, ASG is developing biosensors capable of rapidly detecting and measuring dilute concentrations of multiple proteins from a single drop of sample solution. We are initially targeting the detection and measurement of proteins in biopharmaceutical manufacturing where our technology should enable better detection and control of impurities resulting in lower cost medications with fewer side effects. Once developed we envision many potential applications in medicine and the life sciences including in areas such as cancer therapeutic diagnostics where more timely and accurate diagnosis can lead to better treatment and longer better lives for patients. Our long term vision is to make diagnostics low cost and rapid so that more people have access to good health and medical care.

Articulate Biosciences

Articulate Biosciences is developing cushioning and lubricating injectable gels for treating osteoarthritis and other soft tissue diseases.  For more information, visit the Articulate Biosciences website.

Cam Med

Cam Med is developing a wearable, disposable patch pump for injectable drugs with a breakthrough, patent-issued design enabling:

1. a greatly improved user experience through a conformable, ultra-thin, miniature bandage-like shape and form;
2. a 90% reduction in cost to produce vs. existing patch pumps, making it cost-competitive with pens,
3. active control, Bluetooth connectivity and sensor-augmented delivery; and
4. the potential to deliver multiple medications from a single device.

Flow Forward Medical

Flow Forward Medical, Inc is developing the Arteriovenous Fistula Eligibility (AFE) System™, a novel medical device that rapidly dilates peripheral veins for use in creating reliable and durable arteriovenous fistula (AVF) vascular access sites for hemodialysis. The AFE System is a small, temporary, external blood pump system that stimulates veins to enlarge using rapid blood flow, making more patients eligible for an AVF and increasing success rates after AVF surgery. Establishment of a durable and reliable AVF reduces morbidity and mortality in hemodialysis patients, as well as the overall cost of their care.

Gel4Med

Gel4Med is preclinical stage company focused at advancing tissue regeneration utilizing its smart materials technology. Founded out of the Harvard Innovation Lab (Harvard University) and M2D2 (University Massachusetts), Gel4Med has raised seed funding from notable investors like Peter Thiel, NIH, NSF, DoD to fund our products engine. Gel4Med's will initially focus on improving the outcomes in integument tissue regeneration, a large market ripe for innovation. In 2020, we will launch our first product that aims to enable surgeons with a topical antimicrobial regenerative matrix technology to address treatment needs of over 8 Million Americans with difficult to treat infected wounds.

KnipBio

KnipBio, Inc., is a Massachusetts-based company pioneering advanced nutritional solutions for animal feeds from low-cost and sustainable feedstocks. Using innovative biotechnology, the company has developed KnipBio Meal - a range of premium aquafeed ingredients built around our PROTEINplus' technology that combine immunonutrients with single cell protein. KnipBio is committed to maintaining a level of transparency to promote sustainable and environmentally sound practices.

LaunchPad Medical

LaunchPad Medical is developing adhesive solutions for bone repair. Patients and doctors desire better products to repair bone that provide immediate load-bearing strength to achieve a faster and less painful return to activity. Tetranite® is an injectable, synthetic biomaterial and will be the world’s first bioresorbable bone adhesive that has instant adhesive strength to treat fractured bone and stabilize metal hardware in compromised bone through less invasive procedures. The commercialization of this unique biomaterial will revolutionize treatment options and improve the standard of care.

LivOnyx

Did you know that 1 out of 25 patients that go into the hospital come out with an infection they didn’t have to start with, and those infections could be largely prevented with better hand hygiene? LivOnyx studied the behavior behind why something as simple as washing hands, which turns out to be more complex than you would imagine, doesn’t happen as it ‘should’ in healthcare settings. Rejecting the hand hygiene status quo, LivOnyx is developing a novel, fully automated hand sanitization device and antiseptic, that will be at every patient’s bedside where you need it, in order to sanitize and dry hands the right way, every time in just 3-5 seconds.

NEATCap Medical

The mission of NEATCap Medical, LLC is to develop and deliver products aimed at protecting hearing, reducing stress, facilitating sleep, and promoting brain development in neonates. NEATCap Medical's first product is DREAMIES^TM -- a passive hearing protection device for neonates undergoing hospital critical care in neonatal intensive care units. DREAMIES are currently an investigationa device in the U.S. DREAMIES are a patented, over-the-ear noise protection device designed for care of the premature infant to full-term newborn population. DREAMIES offer improved performance and ease-of-use as compared with current commercial earmuffs and earplugs. DREAMIES are built in a range of sizes, with ear cup shape and sound filtering characteristics designed for care of this special neonate population.

Nuclease Probe Technologies

Nuclease Probe Technologies harnesses the power of enzymes produced by bacteria to determine the most effective antibiotic therapy required to treat patients with a life-threatening condition called Sepsis. Sepsis is a leading cause of disease and death worldwide. 270,000 people die each year in the US and Sepsis costs US hospitals over $24 Billion annually. NPT delivers gold standard lab results 10 X faster than current laboratory instruments allowing for early intervention with targeted antibiotics. Early treatment has been shown to save lives, make patients better faster, and reduce length of stay.

Versatope Therapeutics

Versatope Therapeutics is an immuno-therapeutic company that uses recombinant outer membrane vesicles (OMVs) to deliver therapeutics and vaccines with superior effectiveness to current methods. The team is developing a universal influenza vaccine candidate that combines and displays multiple sequences from diverse strains of flu virus on a single nano-vesicle. Versatope uses protein structures and analytical software to design vaccines using domains of proteins that are less likely to change, with the potential for protection against multiple seasonal and pandemic strains of influenza.